Document:

EX-10.13

 Exhibit 10.13 

BioAtla, LLC 
 Effective July l, 2018 

Jay M. Short, PhD 
 C/o BioAtla, LLC 

Re: Severance Agreement 
 Dear Jay, 

BioAtla, LLC (the “Company”), is pleased to provide the following Severance Agreement (the “Agreement”) to you. This
Agreement will be effective only if you sign and return this Agreement within ten (10) business days. 

1.    Eligibility / Severance Benefits. If (i) your employment ceases at any time following a Change in Control
(either, a “Qualifying Termination”), and (ii) you satisfy the Release Requirement (as defined in Section 2 below), then you will receive the following “Severance Benefits”: 

1.1.    Severance Payment. A severance payment equal to twenty-four (24) months of your final monthly
base salary (the “Severance Payment”). The Severance Payment will be paid to you, in the form of a lump sum payment, subject to required payroll deductions and tax withholdings, within twenty (20) business days following the
Release Effective Date (as defined in Section 2 below). For purposes of calculating the Severance Payment, your final base salary will be calculated prior to giving effect to any reduction in base salary that would give rise to your right to
resign for Good Reason. 
 1.2.    Prorata Bonus Payment. An amount equal to a prorated portion of your
target bonus amount for the Termination Year (the “Target Bonus Amount”) that corresponds to your service during the Termination Year (the “Prorata Bonus Payment”), which shall be calculated by multiplying
(i) the Target Bonus Amount, by (ii) a fraction, the numerator of which is the number of days during the Termination Year that you were employed by the Company and the denominator of which is three hundred and sixty-five (365). The Prorata
Bonus Payment will be paid to you, in the form of a lump sum payment, subject to required payroll deductions and tax withholdings, within twenty (20) business days following the Release Effective Date. For purposes of calculating the Target
Bonus Amount for any Termination Year, your final base salary will be calculated prior to giving effect to any reduction in base salary that would give rise to your right to resign for Good Reason. 

1.3.    Prior Year Bonus Payment. If the Qualifying Termination occurs prior to the date on which bonuses
are paid for the year immediately preceding the Termination Year (the “Prior Year”), an amount equal to your full target bonus amount for the Prior Year (the “Prior Year Bonus Payment”). The Prior Year Bonus Payment
will be paid to you (if applicable), in the form of a lump sum payment, subject to required payroll deductions and tax withholdings, within twenty (20) business days following the Release Effective Date. For purposes of calculating the Prior
Year Bonus Payment, your final base salary will be calculated prior to giving effect to any reduction in base salary that would give rise to your right to resign for Good Reason. 

1.4.    Double Trigger Accelerated Vesting. The vesting and exercisability of all unvested time-based
vesting equity awards then held by you shall accelerate such that all shares become immediately vested and exercisable, if applicable, by you upon such termination and shall remain exercisable, if applicable, following your termination as set forth
in the applicable equity award documents. With respect to any performance-based vesting equity award, such award shall continue to be governed in all respects by the terms of the applicable equity award documents. 

 2.    Conditions to Receipt of Severance Benefits. To be
eligible for any of the Severance Benefits pursuant to Section 1 of this Agreement, you must satisfy the following release requirement (the “Release Requirement”): return to the Company a signed and dated general release of all
known and unknown claims in a termination agreement acceptable to the Company (the “Release”) within the applicable deadline set forth therein, but in no event later than forty-five (45) calendar days following your termination
date, and permit the Release to become effective and irrevocable in accordance with its terms (such effective date of the Release, the “Release Effective Date”). No Severance Benefits will be paid hereunder prior to the Release
Effective Date. Accordingly, if you refuse to sign and deliver to the Company an executed Release or you sign and deliver to the Company the Release but exercise your right, if any, under applicable law to revoke the Release (or any portion
thereof), then you will not be entitled to any severance, payment or benefit under this Agreement. 

3.    IRS Code Section 409A. All payments provided hereunder are intended to constitute
separate payments for purposes of Treasury Regulation Section 1.409A-2(b) (2). If the Company determines that any benefits provided under this Agreement constitute “deferred compensation”
under Section 409A of the Internal Revenue Code of 1986 as amended (“Section 409A”), such benefits will not commence in connection with your termination of employment unless such termination also qualifies as
a “separation from service” with the Company within the meaning of Treasury Regulation Section 1.409A-1(h) (without regard to any permissible alternative definition thereunder)
(“Separation from Service”). If the Company determines that any benefits provided under this Agreement constitute “deferred compensation” under Section 409A and you are a “specified employee” of the Company
or any affiliate thereof (or any successor entity thereto) within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of your Separation from Service, then the payment of any such benefits shall be delayed until the earlier of:
(i) the date that is six (6) months and one (1) day after the date of your Separation from Service, or (ii) the date of your death (such date, the “Delayed Payment Date”), and the Company (or the successor entity
thereto, as applicable) shall (A) pay to you a lump sum amount equal to the sum of the benefit payments that otherwise would have been paid to you on or before the Delayed Payment Date, without any adjustment on account of such delay, and
(B) continue the benefit payments in accordance with any applicable payment schedules set forth for the balance of the period specified herein. In addition to the above, to the extent required to comply with Section 409A and the applicable
regulations and guidance issued thereunder, if the applicable deadline for you to execute (and not revoke) the applicable Release spans two calendar years, the Release Effective Date shall not be deemed to occur until the second calendar year. 

4.    Section 280G; Limitations on Payment. 

4.1.    If any payment or benefit you will or may receive from the Company or otherwise (a “280G
Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the
“Excise Tax”), then any such 280G Payment provided pursuant to this Agreement (a “Payment”) shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of
the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause
(x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding
sentence and the Reduced Amount 

 
is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) that results in the greatest economic
benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”). 

4.2.    Notwithstanding any provision of Section 4.1 to the contrary, if the Reduction Method or the Pro Rata
Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction
Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic
benefit for Executive as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or
eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Payments that
are not deferred compensation within the meaning of Section 409A. 
 4.3.    Unless you and the Company
agree on an alternative accounting firm or, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control transaction shall perform the foregoing calculations. If
the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized accounting or law firm to make the
determinations required by this Section 4. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the
accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a
280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested by you or the Company. 

4.4.    If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of
Section 4.1 and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you agree to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause
(x) of Section 4.1) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 4.1, you shall have no obligation to
return any portion of the Payment pursuant to the preceding sentence. 
 5.    Definitions. 

5.1.    Change in Control. For purposes of this Agreement, the term “Change in Control”
means a transaction or series of transactions (including by way of merger, consolidation, recapitalization, reorganization or sale of stock or units), the result of which is that Jay Short and Carolyn Short are, after giving effect to such
transaction, no longer, in the aggregate, in control, directly or indirectly (including through one or more intermediaries and/or voting rights agreements), of more than 50% of the voting power of the outstanding voting securities of the surviving
entity of such transaction, and including a capital raising transaction in which the Company is the surviving entity. 

5.2.    Termination Year. For purposes of this Agreement, “Termination Year” means the
fiscal year in which your Company employment is terminated for any reason. 

 6.    Miscellaneous. Nothing in this Agreement is intended
to alter the at-will nature of your employment with the Company or the terms of any offer letter and/or employment-related agreement with the Company. This Agreement constitutes the complete, final and
exclusive embodiment of the entire agreement between the Company and you with regard to Severance Benefits, and it supersedes and replaces any other agreements (whether written or unwritten) you may have with the Company concerning any severance
benefits. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Agreement may
not be modified or amended except in a written agreement approved by the Board and signed by you and a duly authorized and independent member of the Board. This Agreement will bind the heirs, personal representatives, successors and assigns of both
you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect
any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This Agreement shall be construed
and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement,
or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile signatures,
and signatures sent via PDF, shall be equivalent to original signatures. 
 To indicate your understanding and acceptance of this Agreement, please sign and
date below, and return this Agreement to the Company. 
 We look forward to a continued productive employment relationship. 

Sincerely, 
 BioAtla, LLC 

 

	
	
	/s/ Richard Waldron
	Richard Waldron
	Chief Financial Officer

 Understood and Accepted: 
  

	
	
	/s/ Jay M. Short
	Jay M. Short, PhDEX-10.14

 Exhibit 10.14 

 
 

 
 August 2, 2018 

Mr. Scott Smith 
 100 Barclay Street, 17L 

New York, NY 10007 
 Dear Scott: 

On behalf of BioAtla LLC (the “Company”), I am pleased to confirm the terms of your employment offered by the Company in
connection with your role as President of the Company. 
 1. Position: Your employment as President shall be a full-time position as an
officer of the Company reporting to the Chief Executive Officer of the Company, Jay M. Short, Ph.D., or the Board of Directors of the Company. At a future date, as determined by Dr. Short in his discretion, you may also take on the
responsibilities of Chief Executive Officer (CEO) of the Company. You acknowledge that Dr. Short may direct you to take on the responsibilities of CEO without any changes to your salary or other compensation from the Company. 

2. Work Location: Your principal place of employment will be the Company’s offices which are currently located in San Diego, California,
subject to business travel requirements. As a condition of your employment, you will be required to relocate your primary residence to the San Diego metropolitan area on or before February 1, 2019. 

3. Start Date: Your first day of employment on a part-time basis will be August 23, 2018 (the “Start Date”). Your first
day of employment on a full-time basis will be October 1, 2018. 
 4. Salary: You will receive an initial base salary at the annualized
rate of Five Hundred Thousand Dollars ($500,000), which shall be subject to standard payroll deductions and withholdings and paid on a regular basis in accordance with the Company’s normal payroll procedures and policies. Such base salary shall
be pro-rated during your employment on a part-time basis based on your hours worked. You will be eligible to participate in the Company’s flexible paid time off policy, and also be eligible to participate
in the employee benefit plans and programs that the Company offers to other executive employees of the Company, including health, life, disability and dental insurance, and participation in the Company’s 401(k) retirement savings plan, pursuant
to the terms and conditions of the benefit plans and applicable Company policies and procedures (as such plans, policies and procedures may be terminated or changed from time to time in the Company’s discretion) . 

5. Bonus: You will be eligible to earn annual discretionary incentive compensation in any amount up to fifty percent (50%) of your then
current base salary (subject to standard 

 
payroll deductions and withholdings), based on achievement of individual and corporate performance targets, metrics and/or management by objectives (collectively, “MBOs”) to be
determined and approved by the Company in its discretion. Annual incentive compensation is paid on an annual basis, after the close of the fiscal year and after determination by the Company of (a) the level of achievement of the applicable
individual and corporate performance targets, metrics and/or MBOs, and (b) the amount of any annual incentive compensation earned by you. No annual incentive compensation amount is guaranteed and, in addition to the other conditions for earning
such compensation, you must remain an employee of the Company on the date on which the annual incentive compensation is paid in order to be eligible for any annual incentive compensation. This annual incentive compensation program will be the only
incentive compensation, commission, or other bonus program that will apply to you. For the 2018 annual incentive compensation period, your eligibility will be prorated based on the period of employment on a full-time basis. 

6. Profits Interests: Following the Start Date and subject to Board approval and your signing (within ten business days of receipt thereof) of
such agreements and other documents as the Board may require, you will receive a grant of a total of 3,500,000 Class B Profits Interest Units of the Company (the “Units”) under the Company’s Amended and Restated Profits
Interest Incentive Plan or a successor equity plan (“Plan”). The Units will be subject to the terms of the Plan and the Unit Issuance Agreement between you and the Company evidencing the grant (the “Issuance
Agreement”) as well as the Company’s Second Amended and Restated Operating Agreement (the “Operating Agreement”). The Units generally are intended to qualify as “profits interests” under Revenue Procedure 93-27 and Revenue Procedure 2001-43 and thus shall not participate with respect to any Net Income or Net Loss of the Company prior to the issuance date of the Units (nor shall
the Units be attributed any value of the assets of the Company held immediately prior to the issuance date of such Units). Subject to the terms of the Plan, the Issuance Agreement and the Operating Agreement, and your continuous service, the Units
will vest as follows: (a) One Million Seven Hundred Fifty Thousand (1,750,000) of the Units will vest over a period of four (4) years in accordance with the following schedule: twenty-five percent (25%) of such Units shall vest after the
first twelve (12) months of continuous service from your Start Date and the balance of such Units (totaling 1,312,500 Units) shall vest in equal monthly installments over the next three (3) years of continuous service; and (b) One
Million Seven Hundred Fifty Thousand (1,750,000) of the Units will vest as follows: (i) should you be appointed CEO and President at any point during the four (4)-year period following the Start Date, twenty-five percent (25%) of such Units
shall vest upon the later of the date of your appointment as CEO and President (the “Appointment Date”) and the date of the end of twelve (12) months of continuous service from your Start Date, an amount equal to the product of
(x) 1/48 of such Units and (y) the positive number of months, if any, equal to the difference between the number months following your Start Date in which the Appointment Date occurred and the
12th month following your Start Date shall vest on the Appointment Date, and thereafter the balance of such Units will vest following the Appointment Date in equal monthly installments until the
date of four (4) years of continuous service from your Start Date; and (ii) should you not be appointed President and CEO within four (4) years of your Start Date, the full amount of such Units shall vest on the date of the end of the
first 48 months of continuous service from your Start Date. In addition to the other terms and conditions of the Plan, the Units shall be subject to the “Participation Threshold” as described in the Plan, which will generally be equal to
or greater than the net fair value of the Company on the date of grant in each case as determined by the 

  
 2 

 
Board. You acknowledge that, inasmuch as the Units are wholly subject to Board approval, the terms and conditions of the Plan, the Issuance Agreement and the Operating Agreement, nothing in this
Offer Letter shall vary the terms of any Issuance Agreement signed by the Company and you and in the event of a conflict between this Offer Letter and any Issuance Agreement, the terms of the Issuance Agreement shall govern. 

7. NewCo Equity: Following the Start Date and subject to Board approval and your signing (within ten business days of receipt thereof) of such
agreements and other documents as the Board may require, you will receive a grant of a total of One Million Seven Hundred Fifty Thousand (1,750,000) ordinary units of NewCo (“NewCo Units”), a limited liability company established by
the Company to which the Company is transferring its holdings of common stock in F1 Oncology Inc. Subject to the terms of the plan of transfer of the F1 Oncology shares and your continuous service to the Company, the NewCo Units will vest over a
period of four (4) years in accordance with the following schedule: twenty-five percent (25%) of such Units shall vest on the date of the end of the first twelve (12) months of continuous service to the Company following your Start Date
and the balance of such NewCo Units shall vest in equal monthly installments over the next three (3) years of continuous service to the Company. 

8. Relocation Benefit: The Company will advance to you a cash payment in an amount such that you will receive a net payment in the amount of
One Hundred Twenty-Five Thousand Dollars ($125,000) after deduction of all applicable withholding taxes, payable in a lump sum on the first administratively practicable payroll pay date following the Start Date (the “Relocation
Benefit”). You agree and acknowledge that if (a) you do not relocate your primary residence to the San Diego metropolitan area on or before February 1, 2019, and (b) the Company terminates your employment based on your
failure to relocate within this time-frame (which termination shall be for Cause as defined below), you must repay the entire Relocation Benefit to the Company within thirty (30) days following your termination date. 

9. Following the Start Date and the period of your employment on a part-time basis, your employment with the Company shall be on a full-time
basis and you agree that you will devote your full working time and ability to the performance of your duties. You will further give the Company your undivided loyalty, and refrain during your employment from engaging in any activity that might
interfere with your duties to the Company or create a potential or actual conflict of interest. 
 10. In your work for the Company, you
will be prohibited from using or disclosing any confidential, proprietary or trade secret information of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be required to use only information that
is generally known and used by persons with training and experience comparable to your own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by the Company. You agree that you will
not bring onto Company premises or use in your work for the Company any unpublished documents or property belonging to any former employer or third party that you are not authorized to use and disclose. You represent further that you have disclosed
to the Company any contract you have signed that might restrict your activities on behalf of the Company. By accepting employment with the Company, you are representing that you will be able to perform your job duties within these parameters. 

  
 3 

 11. Termination of Employment: 

(a) Your employment with the Company may be terminated by you or the Company at any time for any reason upon written notice. In the event that
your employment is terminated by the Company without Cause (as defined below), the Company shall provide you with severance in a total amount equal to twelve (12) months’ pay at your final base salary rate, payable in the form of salary
continuation. Any obligation of the Company to provide you with the payments described in the preceding sentence is conditioned on your signing a timely and effective general release of claims in a form acceptable to the Company and your continued
compliance with the terms of this Offer Letter. Such release shall be considered timely if it is executed and delivered (and no longer subject to revocation, if applicable) within sixty (60) days following the date of the termination of your
employment and any payments to which you are entitled pursuant to this Section shall commence on the Company’s first regular pay date following the effective date of the aforementioned release of claims and the first such payment shall be
retroactive to the day immediately following the date of the termination of your employment. 
 (b) For purposes of this Offer Letter,
“Cause” shall mean the following, as determined by the Board in its reasonable judgment: (i) your failure to perform, or material negligence in the performance of, your duties and responsibilities to the Company or any of its
affiliates; (ii) your material breach of this Offer Letter or any other agreement between you and the Company or any of its affiliates; (iii) willful misconduct by you that is or could reasonably be expected to be materially harmful to the
business interests or reputation of the Company or any of its affiliates; (iv) your conviction of (or the pleading by you of nolo contendere to) any felony; (v) your failure to relocate your primary residence as required by Section 2
above; or (vi) your failure to commence employment on a full-time basis as required by Section 3 above. 
 (c) Notwithstanding
anything to the contrary contained in this Offer Letter, in the event that at the time of your separation from service you are a “specified employee,” as hereinafter defined, any and all amounts payable under this Section in connection
with such separation from service that constitute deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended, (“Section 409A”), as determined by the Company in its sole
discretion, and that would (but for this sentence) be payable within six (6) months following such separation from service, shall instead be paid on the earlier of (i) the expiration of the six (6)-month period measured from the date of
your separation from service, and (ii) the date of your death. For purposes of the preceding sentence, “separation from service” shall be determined in a manner consistent with subsection (a)(2)(A)(i) of Section 409A and the term
“specified employee” shall mean an individual determined by the Company to be a specified employee as defined in subsection (a)(2)(B)(i) of Section 409A. For purposes of Section 409A, your right to receive installment payments
pursuant to this Offer Letter shall be treated as a right to receive a series of separate and distinct payments. Except as expressly stated in this Section or as provided in any employee benefit plan of the Company, or as required by the
Consolidated Omnibus Budget Reconciliation Act (COBRA), any and all payments, compensation and benefits provided to you by the Company shall cease as of the date of the termination of your employment. 

  
 4 

 12. In addition to the compensation package described above, you will be reimbursed for any
Company-approved and IRS permitted out-of-pocket expenses (other than Company-approved expenses which are charged by you on Company credit cards), in accordance with the
Company’s policies. 
 13. As a condition of employment, you must agree to sign and abide by the Company’s Employee Inventions and
Non Disclosure Agreement (“EINDA”). You acknowledge and agree that the Company’s obligation to provide you with any severance payments pursuant to Section 11 above is conditioned upon your continued compliance with all
terms of the EINDA. 
 14. You also agree to comply with the Company’s rules, policies and procedures as they are issued from time to
time by the Company. 
 15. Before commencing employment, you must provide proof of your identity and authorization to work in the United
States, and till out a form 1-9 as required by federal immigration laws. Further, this offer is contingent upon your successful completion of a background check to the satisfaction of the Company. 

16. To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the
Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Offer Letter, your
employment with the Company, or the termination of your employment from the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law,
by final, binding and confidential arbitration by JAMS, Inc. (“JAMS”) or its successors by a single arbitrator. The arbitration will be held in San Diego, California, or in such other location as then-agreed by the parties. BOTH
YOU AND THE COMPANY ACKNOWLEDGE THAT BY AGREEING TO THIS ARBITRATION PROCEDURE, YOU EACH WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTE THROUGH A TRIAL BY JURY OR JUDGE OR ADMINISTRATIVE PROCEEDING. Any such arbitration proceeding will be governed
by JAMS’ then applicable rules and procedures for employment disputes (which can be found at https://www.jamsadr.com/rukes-employment-arbitration/, and which will be provided to you on request). In any such proceeding, the arbitrator shall:
(a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision including the arbitrator’s essential
findings and conclusions and a statement of the award. You and the Company shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law. Nothing in this Offer Letter is intended to prevent either the Company
or you from obtaining injunctive relief in any court of competent jurisdiction to prevent irreparable harm pending the conclusion of any such arbitration, including but not limited to pursuant to the EINDA. The Company shall pay all filing fees in
excess of those which would be required if the dispute were decided in a court of law, and shall pay the arbitrator’s fees and any other fees or costs unique to arbitration. Any awards or orders in such arbitrations may be entered and enforced
as judgments in the federal and state courts of any competent jurisdiction. 

  
 5 

 17. This Offer Letter and the EINDA sets forth the entire agreement between you and the
Company with respect to the subject matter thereof. Once signed by you and a duly authorized officer of the Company, this Offer Letter and the EINDA will become legally binding contracts, and will supersede all prior agreements, promises, and
understandings (either oral or written) between you and the Company. 
 18. This Offer Letter may not be amended or modified except by a
written modification signed by you and a duly authorized officer of the Company, with the exception of those changes expressly reserved to the Company’s discretion in this Offer Letter. This Offer Letter will be governed by and construed in
accordance with the laws of the State of California. The validity or unenforceability of any provision of this Offer Letter, or any terms hereof, shall not affect the validity or enforceability of any other provision or term of this Offer Letter.

 19. All payments made pursuant to this Offer Letter shall be subject to withholding of applicable income and employment taxes. The
Company may withhold from any payments made under this Offer Letter all authorized or legally required deductions and withholdings, including but not limited to income, employment and social insurance taxes. Nothing in this Offer Letter shall create
any obligation on the part of the Company to indemnify, reimburse, gross up, or otherwise compensate you for any taxes, interest, penalties, costs, losses, damages, or expenses arising out of any violation of tax laws or any corresponding provision
of law. Your signature below constitutes your agreement with the Company’s employment terms and conditions and this agreement is contingent on final references and standard background check. 

To confirm that you agree to the terms stated in this Offer Letter, please sign and date the enclosed copy of this Offer Letter and return it to me as soon as
possible, but no later than August 3, 2018. 
 On behalf of the Company, I am very pleased to make this offer and look forward to you joining our team.

  

			
	 Very truly yours, 

	
	 BIOATLA, LLC 

		
	By:	 	       /s/ Jay M. Short

	Name:   Jay M. Short, Ph.D.
	Title:     Chairman, CEO & President

  

			
	 I agree to the terms stated in this letter.

		
	 Dated:
	 	 
	
	 
	 Scott Smith

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]